VIDEO: Cabozantinib triplet regimen continues to show improved PFS in advanced RCC
Click Here to Manage Email Alerts
SAN FRANCISCO — In this video, Toni K. Choueiri, MD, who was the senior author, discusses an analysis of COSMIC-313 presented at ASCO Genitourinary Cancers Symposium.
“What we tried to do here was follow up on the ESMO 2022 presentation where the triplet of [cabozaninib, nivolumab and ipilimumab] did result in a statistically significant and clinically relevant PFS advantage over the doublet of [nivolumab and ipilimumab],” Choueiri, Jerome and Nancy Kohlberg professor of medicine at Harvard Medical School and attending physician in solid tumor oncology, director of the Genitourinary Oncology Disease Center, and director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, said.
In this analysis, the researchers stratified PFS outcomes among patients with first-line advanced renal cell carcinoma receiving cabozantinib (Cabometyx, Exelixis) plus nivolumab (Opdivo, Bristol Myers Squibb) and ipilimumab (Yervoy, Bristol Myers Squibb) compared with patients receiving only nivolumab and ipilimumab by the individual International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups.
Reference:
- Powles T, et al. Abstract 605. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 16-18, 2023; San Francisco.
Collapse
Healio Interviews
Click Here to Manage Email Alerts